ODAC backs ApoPharma's iron chelator, but lacks harmony on prostate cancer trials
This article was originally published in Scrip
Executive Summary
Canadian drug maker ApoPharma, a unit of Apotex, won the backing of a US FDA advisory panel on 14 September for the company's experimental oral iron chelator Ferriprox (deferiprone) as a treatment for patients with transfusional iron overload when current chelation therapy is inadequate.